Annual Net Income
-$177.12 M
-$75.17 M-73.74%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual net profit is -$177.12 million, with the most recent change of -$75.17 million (-73.74%) on December 31, 2023.
- During the last 3 years, LXRX annual net income has fallen by -$118.55 million (-202.39%).
- LXRX annual net income is now -236.11% below its all-time high of $130.13 million, reached on December 31, 2019.
Performance
LXRX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$64.81 M
-$11.38 M-21.30%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly net profit is -$64.81 million, with the most recent change of -$11.38 million (-21.30%) on September 30, 2024.
- Over the past year, LXRX quarterly net income has dropped by -$16.41 million (-33.92%).
- LXRX quarterly net income is now -128.67% below its all-time high of $226.09 million, reached on September 30, 2019.
Performance
LXRX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$216.39 M
-$14.29 M-7.07%
September 30, 2024
Summary
- As of February 7, 2025, LXRX TTM net profit is -$216.39 million, with the most recent change of -$14.29 million (-7.07%) on September 30, 2024.
- Over the past year, LXRX TTM net income has dropped by -$22.81 million (-11.78%).
- LXRX TTM net income is now -231.56% below its all-time high of $164.49 million, reached on September 30, 2019.
Performance
LXRX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
LXRX Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -73.7% | -33.9% | -11.8% |
| 3 y3 years | -202.4% | -177.1% | -123.0% |
| 5 y5 years | -46.9% | -128.7% | -266.3% |
LXRX Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -101.8% | at low | -177.1% | at low | -146.6% | at low |
| 5 y | 5-year | -236.1% | at low | -178.5% | +6.2% | -266.3% | at low |
| alltime | all time | -236.1% | at low | -128.7% | +6.2% | -231.6% | at low |
Lexicon Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$64.81 M(+21.3%) | -$216.39 M(+7.1%) |
| Jun 2024 | - | -$53.43 M(+10.4%) | -$202.11 M(+4.4%) |
| Mar 2024 | - | -$48.40 M(-2.7%) | -$193.58 M(+9.3%) |
| Dec 2023 | -$177.12 M(+73.7%) | -$49.76 M(-1.5%) | -$177.12 M(+12.2%) |
| Sep 2023 | - | -$50.52 M(+12.5%) | -$157.86 M(+20.8%) |
| Jun 2023 | - | -$44.90 M(+40.6%) | -$130.72 M(+18.4%) |
| Mar 2023 | - | -$31.93 M(+4.7%) | -$110.40 M(+8.3%) |
| Dec 2022 | -$101.94 M(+16.2%) | -$30.49 M(+30.4%) | -$101.94 M(+5.0%) |
| Sep 2022 | - | -$23.39 M(-4.9%) | -$97.06 M(+0.3%) |
| Jun 2022 | - | -$24.59 M(+4.7%) | -$96.80 M(+7.2%) |
| Mar 2022 | - | -$23.48 M(-8.3%) | -$90.28 M(+2.9%) |
| Dec 2021 | -$87.76 M(+49.8%) | -$25.61 M(+10.8%) | -$87.76 M(+29.7%) |
| Sep 2021 | - | -$23.12 M(+28.0%) | -$67.64 M(-277.6%) |
| Jun 2021 | - | -$18.07 M(-13.8%) | $38.08 M(-394.7%) |
| Mar 2021 | - | -$20.96 M(+281.4%) | -$12.92 M(-77.9%) |
| Dec 2020 | -$58.57 M(-145.0%) | -$5.50 M(-106.7%) | -$58.57 M(-43.8%) |
| Sep 2020 | - | $82.60 M(-219.6%) | -$104.22 M(-365.4%) |
| Jun 2020 | - | -$69.07 M(+3.7%) | $39.27 M(-54.0%) |
| Mar 2020 | - | -$66.61 M(+30.3%) | $85.32 M(-34.4%) |
| Dec 2019 | $130.13 M(-208.0%) | -$51.14 M(-122.6%) | $130.13 M(-20.9%) |
| Sep 2019 | - | $226.09 M(-1082.2%) | $164.49 M(-284.8%) |
| Jun 2019 | - | -$23.02 M(+5.6%) | -$88.99 M(-11.5%) |
| Mar 2019 | - | -$21.80 M(+29.9%) | -$100.53 M(-16.6%) |
| Dec 2018 | -$120.55 M(-2.0%) | -$16.78 M(-38.7%) | -$120.55 M(-4.4%) |
| Sep 2018 | - | -$27.40 M(-20.7%) | -$126.09 M(-2.6%) |
| Jun 2018 | - | -$34.55 M(-17.4%) | -$129.41 M(-0.4%) |
| Mar 2018 | - | -$41.82 M(+87.4%) | -$129.92 M(+5.6%) |
| Dec 2017 | -$122.99 M(-6.4%) | -$22.32 M(-27.3%) | -$122.99 M(-0.1%) |
| Sep 2017 | - | -$30.72 M(-12.4%) | -$123.11 M(-4.1%) |
| Jun 2017 | - | -$35.06 M(+0.5%) | -$128.40 M(-2.3%) |
| Mar 2017 | - | -$34.89 M(+55.5%) | -$131.45 M(+0.0%) |
| Dec 2016 | -$131.44 M(+2707.5%) | -$22.43 M(-37.7%) | -$131.44 M(+490.5%) |
| Sep 2016 | - | -$36.02 M(-5.5%) | -$22.26 M(+3.4%) |
| Jun 2016 | - | -$38.11 M(+9.3%) | -$21.53 M(+87.4%) |
| Mar 2016 | - | -$34.88 M(-140.2%) | -$11.49 M(+145.4%) |
| Dec 2015 | -$4.68 M(-95.3%) | $86.75 M(-345.9%) | -$4.68 M(-95.0%) |
| Sep 2015 | - | -$35.28 M(+25.7%) | -$94.36 M(-5.2%) |
| Jun 2015 | - | -$28.07 M(-0.0%) | -$99.58 M(+2.1%) |
| Mar 2015 | - | -$28.08 M(+857.2%) | -$97.53 M(-2.8%) |
| Dec 2014 | -$100.29 M(-3.7%) | -$2.93 M(-92.8%) | -$100.29 M(-12.6%) |
| Sep 2014 | - | -$40.50 M(+55.6%) | -$114.78 M(+8.3%) |
| Jun 2014 | - | -$26.03 M(-15.6%) | -$105.94 M(-2.8%) |
| Mar 2014 | - | -$30.84 M(+77.1%) | -$108.99 M(+4.7%) |
| Dec 2013 | -$104.13 M(-5.5%) | -$17.41 M(-45.0%) | -$104.13 M(-6.7%) |
| Sep 2013 | - | -$31.66 M(+8.9%) | -$111.58 M(+1.9%) |
| Jun 2013 | - | -$29.08 M(+12.0%) | -$109.47 M(+3.0%) |
| Mar 2013 | - | -$25.97 M(+4.4%) | -$106.32 M(-3.5%) |
| Dec 2012 | -$110.21 M | -$24.87 M(-15.8%) | -$110.21 M(-7.5%) |
| Sep 2012 | - | -$29.54 M(+13.9%) | -$119.18 M(+3.0%) |
| Jun 2012 | - | -$25.93 M(-13.2%) | -$115.75 M(-0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$29.87 M(-11.8%) | -$116.45 M(+0.2%) |
| Dec 2011 | -$116.22 M(+14.2%) | -$33.84 M(+29.7%) | -$116.22 M(+10.3%) |
| Sep 2011 | - | -$26.10 M(-2.0%) | -$105.37 M(-1.3%) |
| Jun 2011 | - | -$26.64 M(-10.1%) | -$106.78 M(+1.4%) |
| Mar 2011 | - | -$29.63 M(+28.8%) | -$105.33 M(+3.5%) |
| Dec 2010 | -$101.78 M(+22.9%) | -$23.00 M(-16.4%) | -$101.78 M(+1.0%) |
| Sep 2010 | - | -$27.51 M(+9.2%) | -$100.78 M(+9.1%) |
| Jun 2010 | - | -$25.19 M(-3.4%) | -$92.41 M(+5.9%) |
| Mar 2010 | - | -$26.07 M(+18.5%) | -$87.29 M(+5.4%) |
| Dec 2009 | -$82.78 M(+7.7%) | -$22.00 M(+15.0%) | -$82.78 M(+8.6%) |
| Sep 2009 | - | -$19.14 M(-4.6%) | -$76.19 M(-5.4%) |
| Jun 2009 | - | -$20.07 M(-6.9%) | -$80.51 M(+0.0%) |
| Mar 2009 | - | -$21.56 M(+39.8%) | -$80.47 M(+4.7%) |
| Dec 2008 | -$76.86 M(+30.7%) | -$15.42 M(-34.3%) | -$76.86 M(+4.4%) |
| Sep 2008 | - | -$23.46 M(+17.1%) | -$73.62 M(+14.5%) |
| Jun 2008 | - | -$20.03 M(+11.6%) | -$64.27 M(+11.1%) |
| Mar 2008 | - | -$17.95 M(+47.4%) | -$57.83 M(-1.6%) |
| Dec 2007 | -$58.79 M(+8.3%) | -$12.18 M(-13.7%) | -$58.79 M(-2.7%) |
| Sep 2007 | - | -$14.11 M(+3.8%) | -$60.44 M(+2.3%) |
| Jun 2007 | - | -$13.59 M(-28.1%) | -$59.08 M(-5.3%) |
| Mar 2007 | - | -$18.91 M(+36.8%) | -$62.40 M(+14.9%) |
| Dec 2006 | -$54.31 M(+49.6%) | -$13.82 M(+8.4%) | -$54.31 M(+57.1%) |
| Sep 2006 | - | -$12.76 M(-24.5%) | -$34.57 M(-3.8%) |
| Jun 2006 | - | -$16.90 M(+56.1%) | -$35.94 M(+6.1%) |
| Mar 2006 | - | -$10.83 M(-283.1%) | -$33.88 M(-6.7%) |
| Dec 2005 | -$36.31 M(-23.0%) | $5.91 M(-141.9%) | -$36.31 M(-15.1%) |
| Sep 2005 | - | -$14.12 M(-4.9%) | -$42.77 M(-0.6%) |
| Jun 2005 | - | -$14.84 M(+11.9%) | -$43.03 M(-4.3%) |
| Mar 2005 | - | -$13.27 M(+2352.1%) | -$44.97 M(-4.7%) |
| Dec 2004 | -$47.17 M(-26.5%) | -$541.00 K(-96.2%) | -$47.17 M(-23.3%) |
| Sep 2004 | - | -$14.38 M(-14.4%) | -$61.51 M(-0.3%) |
| Jun 2004 | - | -$16.79 M(+8.5%) | -$61.69 M(-1.3%) |
| Mar 2004 | - | -$15.47 M(+4.0%) | -$62.52 M(-2.6%) |
| Dec 2003 | -$64.20 M(+7.6%) | -$14.88 M(+2.2%) | -$64.20 M(+1.6%) |
| Sep 2003 | - | -$14.56 M(-17.4%) | -$63.18 M(-3.4%) |
| Jun 2003 | - | -$17.62 M(+2.8%) | -$65.44 M(+4.3%) |
| Mar 2003 | - | -$17.14 M(+23.7%) | -$62.76 M(+5.2%) |
| Dec 2002 | -$59.67 M(+69.7%) | -$13.86 M(-17.5%) | -$59.67 M(+5.0%) |
| Sep 2002 | - | -$16.81 M(+12.5%) | -$56.81 M(+22.9%) |
| Jun 2002 | - | -$14.94 M(+6.3%) | -$46.22 M(+12.1%) |
| Mar 2002 | - | -$14.06 M(+27.7%) | -$41.22 M(+17.2%) |
| Dec 2001 | -$35.17 M(+35.3%) | -$11.01 M(+76.9%) | -$35.17 M(+11.0%) |
| Sep 2001 | - | -$6.22 M(-37.4%) | -$31.69 M(+17.3%) |
| Jun 2001 | - | -$9.94 M(+24.1%) | -$27.01 M(+31.2%) |
| Mar 2001 | - | -$8.01 M(+6.5%) | -$20.58 M(-20.8%) |
| Dec 2000 | -$25.99 M(+108.0%) | -$7.52 M(+388.3%) | -$25.99 M(+40.7%) |
| Sep 2000 | - | -$1.54 M(-56.2%) | -$18.47 M(+9.1%) |
| Jun 2000 | - | -$3.52 M(-73.8%) | -$16.93 M(+26.2%) |
| Mar 2000 | - | -$13.42 M | -$13.42 M |
| Dec 1999 | -$12.50 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual net profit?
- What is the all time high annual net income for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual net income year-on-year change?
- What is Lexicon Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly net income year-on-year change?
- What is Lexicon Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM net income year-on-year change?
What is Lexicon Pharmaceuticals annual net profit?
The current annual net income of LXRX is -$177.12 M
What is the all time high annual net income for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual net profit is $130.13 M
What is Lexicon Pharmaceuticals annual net income year-on-year change?
Over the past year, LXRX annual net profit has changed by -$75.17 M (-73.74%)
What is Lexicon Pharmaceuticals quarterly net profit?
The current quarterly net income of LXRX is -$64.81 M
What is the all time high quarterly net income for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly net profit is $226.09 M
What is Lexicon Pharmaceuticals quarterly net income year-on-year change?
Over the past year, LXRX quarterly net profit has changed by -$16.41 M (-33.92%)
What is Lexicon Pharmaceuticals TTM net profit?
The current TTM net income of LXRX is -$216.39 M
What is the all time high TTM net income for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM net profit is $164.49 M
What is Lexicon Pharmaceuticals TTM net income year-on-year change?
Over the past year, LXRX TTM net profit has changed by -$22.81 M (-11.78%)